institutional access

You are connecting from
Lake Geneva Public Library,
please login or register to take advantage of your institution's Ground News Plan.

Published loading...Updated

Tarsus Pharmaceuticals (NASDAQ:TARS) Research Coverage Started at Oppenheimer

Summary by themarketsdaily.com
Oppenheimer initiated coverage on shares of Tarsus Pharmaceuticals (NASDAQ:TARS – Free Report) in a report published on Monday. The firm issued an outperform rating and a $75.00 price target on the stock. Several other analysts have also recently commented on the company. Barclays reduced their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and […]
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

3 Articles

All
Left
Center
Right
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

americanbankingnews.com broke the news in on Wednesday, June 4, 2025.
Sources are mostly out of (0)

Similar News Topics